Intellia Therapeutics (NTLA) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$511.0 million.
- Intellia Therapeutics' Enterprise Value rose 2234.72% to -$511.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$511.0 million, marking a year-over-year increase of 2234.72%. This contributed to the annual value of -$601.5 million for FY2024, which is 3406.05% up from last year.
- Per Intellia Therapeutics' latest filing, its Enterprise Value stood at -$511.0 million for Q3 2025, which was up 2234.72% from -$459.7 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Enterprise Value registered a high of -$459.7 million during Q2 2025, and its lowest value of -$1.2 billion during Q4 2022.
- In the last 5 years, Intellia Therapeutics' Enterprise Value had a median value of -$791.3 million in 2024 and averaged -$749.3 million.
- Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 13338.34% in 2021, then surged by 3633.88% in 2025.
- Quarter analysis of 5 years shows Intellia Therapeutics' Enterprise Value stood at -$750.8 million in 2021, then plummeted by 58.85% to -$1.2 billion in 2022, then grew by 23.51% to -$912.2 million in 2023, then surged by 34.06% to -$601.5 million in 2024, then grew by 15.04% to -$511.0 million in 2025.
- Its Enterprise Value was -$511.0 million in Q3 2025, compared to -$459.7 million in Q2 2025 and -$503.7 million in Q1 2025.